Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v2.4.0.8
CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2013
Dec. 31, 2012
Current assets:    
Cash and cash equivalents $ 4,413 $ 11,029
Marketable securities 93,799 59,819
Collaboration receivable 2,548 15,635
Prepaid expenses and other current assets 1,913 1,167
Total current assets 102,673 87,650
Property and equipment, net 773 812
Other assets 1,059 1,059
Total assets 104,505 89,521
Current liabilities:    
Accounts payable 884 908
Accrued clinical and development expenses 7,019 5,750
Accrued liabilities 2,041 2,257
Deferred revenue, current 12,722 8,536
Total current liabilities 22,666 17,451
Warrant liability 33,983 32,558
Deferred revenue, non-current 72,809 53,097
Deferred rent 257 268
Total liabilities 129,715 103,374
Commitments and contingencies (Note 7)      
Stockholders' equity (deficit):    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding      
Common stock, $0.001 par value, shares authorized: 150,000,000 shares; issued and outstanding: 57,992,097 shares at June 30, 2013 and 56,431,207 shares at December 31, 2012 58 56
Additional paid-in capital 320,024 309,343
Accumulated other comprehensive gain (loss) (27) 11
Accumulated deficit (345,265) (323,263)
Total stockholders' equity (deficit) (25,210) (13,853)
Total liabilities and stockholders' equity (deficit) $ 104,505 $ 89,521